Navigation Links
Advanced Life Sciences Announces Third Quarter 2008 Financial Results
Date:11/6/2008

96626416.

About Community Acquired Pneumonia (CAP)

CAP is the sixth most common cause of death in the United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. Approximately 5.6 million cases of CAP are diagnosed each year in the United States with 10 million physician visits, resulting in an estimated total annual expenditure of $2 billion dollars for prescribed antibiotics to treat CAP. CAP is potentially fatal if not treated properly, and the bacteria that cause CAP are developing resistance to current standard of care treatments.

Macrolides and penicillins are currently the front-line treatments for respiratory tract infections such as CAP. As macrolide and penicillin resistance grows and has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging resistance.

About Cethromycin

Cethromycin has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria, certain Gram-negative bacteria and atypical organisms associated with respiratory tract infections. In in vitro tests, it appears to be effective against penicillin- and macrolide-resistant bacteria. Cethromycin has a mechanism of action that may slow the onset of future bacterial resistance. In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. Th
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... the Vienna University of Technology and the Maria ... perfect semiconductor crystals into a silicon nanowire. With ... fast and multi-functional processing units can be accommodated ... research results will be published in the journal ... the cornerstone of future chip technology, but the ...
(Date:7/23/2014)... 23, 2014  AuraSense Therapeutics, the pioneer in developing ... regulatory and immunotherapeutic agents, announced today that ... Therapeutics, executive leadership team as chief financial ... to joining AuraSense Therapeutics, Mr. Snyder was ... of Cellular Dynamics International Inc., where he ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Last year, ... Systems , a leading global provider of data management ... with TrialMaster, a leading-edge system for electronic data capture ... of universal design and study execution tools added TrialMaster ... and much anticipated version of Transform for TrialMaster, is ...
(Date:7/23/2014)... 23 de julio de 2014 ADB ... Compañía) ha anunciado hoy una asociación con Austen ... (ABIA o el Instituto), para el propósito de ... de terapia de señal bioeléctrica (el E-QURE BST ... Instituto, que tiene una importante experiencia en cicatrización ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6
... CITY, Calif. , June 17 OncoMed Pharmaceuticals, Inc. ... global strategic alliance to discover, develop and commercialize novel anti-cancer stem ... a subset of tumor cells believed to play a significant role ... , , ...
... Institute have developed a new, ultra-simple method for ... of a meter thick. The process, which requires ... surface including silicon wafers, could have important implications ... assistant professor in the Department of Physics, Applied ...
... MD ... the functional relevance of a drug treatment on the heart following direct coronary flow ... ... MD Biosciences , a Preclinical Contract Research Organization (CRO), offers in vivo models for ...
Cached Biology Technology:OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 2OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 3OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 4OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 5Researchers develop ultra-simple method for creating nanoscale gold coatings 2MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury 2
(Date:7/23/2014)... , , , , ... , , , , ... healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine focuses almost entirely ...
(Date:7/23/2014)... Washington, DC -- The planet,s soil releases about 60 ... which is far more than that released by burning ... respiration. This enormous release of carbon is balanced by ... and other plant matter, as well as by the ... studies have documented that rising temperatures increase the rate ...
(Date:7/23/2014)... , July 23, 2014 BioCatch, ... detection, announced today it has been named in Gartner,s ... Market Guide replaces Gartner,s well-known Magic Quadrant for Web ... BioCatch as one of several vendors to deliver passive ... will become a standard feature of at least 30% ...
Breaking Biology News(10 mins):Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5Climate change and the soil 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
... whole new interface between nanotechnology and neuroscience, scientists ... to detect, stimulate, and inhibit nerve signals along ... , Harvard chemist Charles M. Lieber and colleagues ... this week in the journal Science. , "We ...
... first time, researchers have developed a way to synthesize a ... it works. , Derived from a fungus discovered clinging to ... certain cancer cells into suicide while leaving healthy cells untouched. ... might have some tremendous potential as a prototype anticancer agent, ...
... Medical Research have discovered a mechanistic link between cellular ... proteins that lead to nerve cell injury and death ... , That link is Protein Disulphide Isomerase ... protein folding in times of cellular stress. Published ...
Cached Biology News:Nanowire arrays can detect signals along individual neurons 2New lab technique churns out fungus' potential cancer fighter 2Key stress protein linked to toxicities responsible for Parkinson's, Alzheimer's 2
... at the 3, 3', 4, and 4' ... an internal standard for the quantification of ... is the theoretical cyclooxygenase metabolite of dihomo-γ-linolenic ... in the plasma of normal humans or ...
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Direct ELISA Assay Diluent, 10 L...
Direct ELISA Assay Diluent - EDTA, 10 L...
Biology Products: